NEWS RELEASES

LEXSTON LIFE SCIENCES CORP. retains marketing consultants and sets Stock Options

Vancouver, British Columbia, September 9, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (the “Company” or “Lexston”) is pleased to announce that the Company has retained Amherst Baer Consultancy Corp. (ABCC”), of Langley, British Columbia, to prepare a marketing campaign for the Company.

ABCC, will provide digital media services, vendor management, marketing and data analytics services to the Company at www.investorsscene.com, and the Company has budgeted $300,000 for such services over an expected twelve-month period. ABCC is a full-service advertising agency and business development corporation that works with a partner ad exchange whose integrated SSPs (supply side platforms) result in access to 2-10 billion daily North American ad impressions. Neither ABCC nor any representatives of ABCC own any securities of the Company directly or indirectly or have any intention to acquire any securities of the Company.

In addition, the Company has granted 780,000 stock options to its directors, officers, consultants and employees. Each stock option is exercisable at $0.18 per share. The options vest immediately and expire on September 8, 2026. All options were granted pursuant to the 10% rolling stock option plan of Lexston dated January 15, 2021 (the “Plan”). As of the date of this news release Lexston has 5,180,000 stock options granted and 5,326 stock options available for future grants.

For more information and to subscribe to the Company’s mailing list, please visit https://lexston.ca/contact/

About Lexston Life Sciences Corp.

Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.

On Behalf of the Board of Directors

LEXSTON LIFE SCIENCES CORP.

Jagdip Bal
Chief Executive Officer
Telephone: (604) 928-8913

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

929 Mainland Street Vancouver, BC V6B 1S3

Phone: (604) 928-8913

Fax: (604) 628-0129

Email: [email protected]

Website: www.lexston.ca

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. All the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com)

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Menu